Bioimpedance Devices for Detection and Management of Lymphedema

Covers use of bioimpedance spectroscopy (BIS) devices to detect, surveil, and help manage lymphedema — including early/subclinical detection in asymptomatic patients with prior surgery, radiotherapy, or trauma to the lymphatic system, surveillance of high‑risk post‑cancer (e.g., breast) patients, monitoring patients who remain symptomatic after conservative therapy, and adjunct assessment in clinically diagnosed lymphedema. Major limitations/requirements: BIS is considered appropriate only in the clinical scenarios described and is investigational outside them; evidence is limited and heterogeneous, BIS offers limited incremental utility for established lymphedema, optimal surveillance frequency is not established (expert guidance suggests every 3–6 months for ≥3 years), and device availability/validation vary.

"Asymptomatic individuals with a history of surgery, radiotherapy, or trauma affecting the lymphatic system when bioimpedance spectroscopy would guide decisions regarding early intervention (e."